Publicacións nas que colabora con M. LLamas Velasco (31)

2024

  1. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  2. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  3. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  4. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  5. Ruxolitinib and Squamous Cell Carcinoma

    Actas Dermo-Sifiliograficas

  6. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501

2022

  1. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*

    British Journal of Dermatology, Vol. 186, Núm. 1, pp. 142-152

  2. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study

    Dermatologic Therapy

  3. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

  4. Knowledge and role of dermatologists in life-threatening infections: a national survey among hospital skin specialists

    Journal of the European Academy of Dermatology and Venereology

  5. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  6. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population

    Journal of the European Academy of Dermatology and Venereology

2021

  1. A new classification of the severity of psoriasis: What’s moderate psoriasis?

    Life, Vol. 11, Núm. 7

  2. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

    Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354

  3. Granulomas in Dermatopathology: Principal Diagnoses - Part 1

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 8, pp. 682-704

  4. Granulomas in Dermatopathology: Principal Diagnoses — Part 2

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 8, pp. 705-724

  5. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

  6. Obesity — A Risk Factor for Psoriasis and COVID-19

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 6, pp. 489-494

  7. Survey on the impact, current needs and expectations of spanish patients with psoriasis. NEXT survey

    Piel, Vol. 36, Núm. 10, pp. 648-656